Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 8% Higher
Deciphera Pharmaceuticals (NASDAQ:DCPH) Trading 8% Higher
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) shares shot up 8% during trading on Friday . The stock traded as high as $19.08 and last traded at $19.03. 5,926 shares were traded during trading, a decline of 99% from the average session volume of 956,942 shares. The stock had previously closed at $17.62.
納斯達克(Deciphera PharmPharmticals,Inc.)股價在週五的交易中飆升8%。該股盤中一度漲至19.08美元,最新報19.03美元。當日成交量為5,926股,較956,942股的平均成交量下降99%。該股此前收盤價為17.62美元。
Analyst Ratings Changes
分析師評級發生變化
Several equities analysts have recently weighed in on DCPH shares. Stifel Nicolaus increased their price target on Deciphera Pharmaceuticals from $11.00 to $18.00 and gave the company a "hold" rating in a report on Tuesday, September 27th. Piper Sandler increased their price target on Deciphera Pharmaceuticals from $13.00 to $18.00 in a report on Sunday, September 11th. SVB Leerink increased their price target on Deciphera Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a report on Monday, September 12th. Cowen started coverage on Deciphera Pharmaceuticals in a report on Monday, August 29th. They set an "outperform" rating and a $25.00 price target on the stock. Finally, Cowen started coverage on Deciphera Pharmaceuticals in a report on Monday, August 29th. They set an "outperform" rating and a $25.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $18.70.
幾位股票分析師最近紛紛買入大昌華嘉的股票。Stifel Nicolaus在9月27日週二的一份報告中將Deciphera PharmPharmticals的目標價從11.00美元上調至18.00美元,並給予該公司“持有”評級。派珀·桑德勒在9月11日週日的一份報告中將他們對Deciphera製藥的目標價從13.00美元上調至18.00美元。SVB Leerink在9月12日週一的一份報告中將Deciphera PharmPharmticals的目標價從21.00美元上調至25.00美元,並給予該公司“跑贏大盤”的評級。考恩在8月29日星期一的一份報告中開始報道Deciphera製藥公司。他們為該股設定了“跑贏大盤”的評級和25.00美元的目標價。最後,考恩在8月29日星期一的一份報告中開始報道Deciphera製藥公司。他們為該股設定了“跑贏大盤”的評級和25.00美元的目標價。兩名股票研究分析師對該股的評級為賣出,五名分析師給予該股持有評級,五名分析師對該股給予買入評級。根據MarketBeat的數據,該公司目前的平均評級為持有,平均目標價為18.70美元。
Deciphera Pharmaceuticals Trading Up 5.0 %
Deciphera PharmPharmticals股價上漲5.0%
The firm has a market cap of $1.24 billion, a PE ratio of -4.32 and a beta of 1.00. The stock has a 50 day simple moving average of $16.44 and a 200-day simple moving average of $12.99.
該公司的市值為12.4億美元,市盈率為-4.32,貝塔係數為1.00。該股的50日簡單移動均線切入位為16.44美元,200日簡單移動均線切入位為12.99美元。
Institutional Investors Weigh In On Deciphera Pharmaceuticals
機構投資者看好Deciphera製藥公司
Institutional investors have recently bought and sold shares of the business. US Bancorp DE grew its position in shares of Deciphera Pharmaceuticals by 100.6% during the second quarter. US Bancorp DE now owns 4,052 shares of the company's stock valued at $53,000 after purchasing an additional 2,032 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Lazard Asset Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $57,000. Denali Advisors LLC grew its position in shares of Deciphera Pharmaceuticals by 33.9% during the first quarter. Denali Advisors LLC now owns 7,900 shares of the company's stock valued at $73,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Deciphera Pharmaceuticals during the first quarter valued at about $98,000. Hedge funds and other institutional investors own 72.29% of the company's stock.
機構投資者最近買賣了該公司的股票。US Bancorp DE在第二季度將其在Deciphera PharmPharmticals的股票頭寸增加了100.6%。US Bancorp DE現在擁有4052股該公司股票,價值5.3萬美元,此前在上個季度又購買了2032股。合併銀行在第一季度購買了Deciphera PharmPharmticals的新頭寸,價值約5.7萬美元。Lazard Asset Management LLC在第一季度購買了Deciphera PharmPharmticals的新頭寸,價值約57,000美元。Denali Advisors LLC在第一季度將其在Deciphera PharmPharmticals的股票頭寸增加了33.9%。Denali Advisors LLC現在擁有7,900股該公司股票,價值73,000美元,上個季度又購買了2,000股。最後,洛杉磯資本管理有限責任公司在第一季度購買了Deciphera製藥公司的新股票,價值約9.8萬美元。對衝基金和其他機構投資者持有該公司72.29%的股票。
About Deciphera Pharmaceuticals
關於Deciphera製藥公司
(Get Rating)
(獲取評級)
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
生物製藥公司Deciphera PharmPharmticals,Inc.通過解決美國和國際上限制對現有癌症療法反應的速度和持久性的關鍵耐藥機制,開發改善癌症患者生命的藥物。它的主要候選藥物是用於治療胃腸道間質瘤(GIST)的QINLOCK,以及用於治療二線GIST的3期試驗。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Deciphera Pharmaceuticals (DCPH)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- 免費獲取StockNews.com關於Deciphera製藥的研究報告(DCPH)
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat:回顧一週9/26-9/30
- 這是買入美光科技的難忘時刻
- 讓Paychex股票為您努力工作
- 利潤下降對CarMax價值主張的挑戰
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《Deciphera PharmPharmticals Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Deciphera製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。